Skip to content
Ecat.nl
Ecat.nl
Home
Docs
Surveys and Studies
Emicizumab pilot study, part I
Emicizumab pilot study, part I
In Newsletter 19 of February 2021 P. Meijer described Emicizumab pilot study, part I
Related items
Analytical Information :
7
A computer-based model to access costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assay
Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays
The responsiveness of different APTT reagents to mild factor VIII, IX and XI deficiencies
Results of a workshop on the inter-laboratory variability of analysis of type 1 factor VIII Inhibitors
The do’s and don’ts of laboratory detection of haemostasis-inhibitors: lessons from a workshop
Analytical performance specifications for hemostasis parameters
The effect of Rivaroxaban on haemostasis assays; results from ECAT surveys
Cases :
8
A patient with acquired factor X deficiency and metastatic carcinoma of the bladder: is there a link between metastasis and factor deficiency in solid tumours?
A patient with mild haemophilia A
Acquired factor X deficiency
Haemophilia B and treatment, case study
Haemophilia A and treatment, case study
A severe haemophilia A patient treated with emicizumab, case study
Acquired haemophilia A
Acquired Hemophilia A, case study
Guidelines :
1
Recommendations for laboratory measurement of factor VIII and FIX type I inhibitors, ICSH recommendations
Haemostatic Cascade :
6
TF Pathway (Extrinsic) with Common Pathway (PT)
Intrinsic Pathway APTT
Coagulation Pathways (All Components)
Activation of TAFI by Thrombin
Activation of Protein C by Thrombin
Activation of Platelets by Thrombin
Quality Issues :
4
Biological Variation of Hemostasis Variables in Thrombosis and Bleeding: Consequences for Performance Specifications
Quality Assurance of replacement therapy and future perspectives
External quality assessment for Factor VIII and Factor IX
The between-laboratoy variation of Factor VIII inhibitor testing
Surveys and Studies :
2
Emicizumab pilot study, part II
Performance of factor IX extended half-life product measurements in external quality control assessment programs
Questions or suggestions?
Clotpedia Support Form
Submit
Success
